CTLA4 and nonpapillary renal cell carcinoma: More importantly, we can predict the clinical benefits of new immune checkpoint-blocking strategies (PD-1/L1 and CTLA4) based on the m6A score, and discover more effective immune targets, thereby improving the immunotherapy effect of ccRCC, and help to develop new immunotherapy drugs.